The risk of recurrent ischemic stroke can be reduced by managing modifiable risk factors and instituting a regimen of mechanism-specific secondary stroke prevention. Strategies for secondary ...

Barcelona, Spain-A new analysis from the Early Use of Existing Preventive Strategies for Stroke (EXPRESS) study confirms that early aggressive treatment of patients with transient ischemic attack (TIA ...

Bayer BAYRY announced that the FDA has accepted its new drug application (NDA) for its investigational, once-daily, oral Factor XIa inhibitor, asundexian, for preventing ischemic stroke in patients ...

Asundexian reduced ischemic stroke risk without increasing major bleeding in the OCEANIC-STROKE study, meeting primary efficacy and safety endpoints. The study included 12,327 patients with acute ...

Recent research findings suggest that people who have a transient ischemic attack (TIA) should get aggressive treatment to help prevent cognitive decline. A transient ischemic attack (TIA), also known ...